Frontiers in Oncology (Oct 2022)

Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma

  • Meng-Ke Liu,
  • Li-Li Cheng,
  • Hong-Mei Yi,
  • Yang He,
  • Xiao Li,
  • Di Fu,
  • Yu-Ting Dai,
  • Hai Fang,
  • Shu Cheng,
  • Peng-Peng Xu,
  • Ying Qian,
  • Yan Feng,
  • Qian Liu,
  • Li Wang,
  • Li Wang,
  • Wei-Li Zhao,
  • Wei-Li Zhao

DOI
https://doi.org/10.3389/fonc.2022.885011
Journal volume & issue
Vol. 12

Abstract

Read online

Lymphoma cells expressing CD5 (CD5+) confer inferior outcome of diffuse large B-cell lymphoma (DLBCL), especially in non–MYC/BCL2 double expressor (non-DE) patients. In tumor microenvironment, CD5+ non-DE tumor revealed increased proportion of immunosuppressive M2 macrophages and enhanced pathways related to macrophage activation and migration. In accordance to M2 activation, lipid metabolism was upregulated, including fatty acid uptake and fatty acid oxidation, which supplied energy for M2 macrophage polarization and activation. Meanwhile, CD36 expression was upregulated and strongly correlated to the proportion of M2 macrophages in CD5+ non-DE DLBCL. In vitro, a DLBCL cell line (LY10) overexpressing CD5 significantly increased M2 proportion in comparison with control when cocultured with peripheral blood mononuclear cells (PBMCs). The addition of metformin significantly decreased the M2 proportion and the CD36 expression level in the coculture systems, indicating that metformin could target altered lipid metabolism and decrease M2 macrophages in DLBCL, especially in CD5+ non-DE lymphoma. In conclusion, enhanced lipid metabolism and M2 macrophage activation contributed to the immunosuppressive tumor microenvironment and could be potential therapeutic targets in CD5+ non-DE DLBCL.

Keywords